Mepivacaína Physan

Mepivacaine, the active ingredient in Mepivacaína Physan, is a local anesthetic presented as a sterile solution for epidural, infiltration and intrapleural use. It provides reversible loss of sensation in targeted tissues in adult patients, facilitating pain control during surgical and diagnostic procedures, and is commonly employed by anesthesiologists.

GNH USA supplies Mepivacaína Physan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Mepivacaine is used to provide local anesthesia in various procedural settings. - Epidural analgesia: provides regional pain relief during labor, childbirth or abdominal surgery. - Infiltration anesthesia for minor surgical procedures: numbs the specific tissue area to allow painless incision and suturing. - Intrapleural analgesia: reduces pain after thoracic interventions by anesthetizing the pleural surface. - Dental procedures requiring local anesthesia: enables pain‑free dental extractions, restorations and periodontal work.

Mepivacaine may cause a range of adverse reactions, most of which are related to its local anesthetic properties.

Common Side Effects: - Tingling or numbness at the injection site. - Mild dizziness or light‑headedness. - Transient headache. - Localized swelling or bruising. - Temporary increase in heart rate. - Mild nausea.

Serious or Rare Side Effects: - Allergic reaction such as rash, itching or anaphylaxis. - Cardiovascular collapse or severe hypotension. - Central nervous system toxicity presenting as seizures or loss of consciousness. - Prolonged numbness beyond the expected duration. - Methemoglobinemia. - Cardiac arrhythmias.

When using Mepivacaína Physan, clinicians should consider several safety measures. - Patient assessment: evaluate cardiac, hepatic and renal function before administration. - Dose limitation: avoid exceeding recommended maximum doses for the specific route. - Monitoring: observe vital signs and neurological status during and after injection. - Contraindications: do not use in patients with known hypersensitivity to amide‑type local anesthetics. - Drug interactions: review concomitant medications that may affect cardiac conduction. - Store at ambient temperature: keep below 25°C, protect from light and moisture, and retain in original packaging.

Mepivacaína Physan can interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid): - Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide) – may potentiate cardiotoxicity. - Monoamine oxidase inhibitors – increase risk of hypertensive crisis. - High‑dose beta‑blockers – can exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - Other local anesthetics – cumulative toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids) – may enhance sedation. - Diuretics – may alter plasma protein binding and affect drug levels.